Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay

UBS has downgraded Novo Nordisk to Neutral from Buy and significantly cut its price target to 340 kroner from 600 kroner. This move reflects growing competitive pressure on the Danish drugmaker's popular weight-loss medications, Ozempic and Wegovy, stemming from both compounding pharmacies and rival Eli Lilly, positioning UBS's new target among the lowest tracked by FactSet.

Analysis

UBS has downgraded Novo Nordisk to neutral from buy, signaling a significant shift in sentiment driven by escalating competitive pressures. The brokerage executed a substantial reduction in its price target to 340 kroner from 600 kroner, citing direct threats to Novo's key weight-loss drugs, Ozempic and Wegovy, from both compounding pharmacies and arch-rival Eli Lilly. This new price target is now the second-lowest among analysts tracked by FactSet, underscoring the bearish nature of the revision. The downgrade is not an isolated opinion; it aligns with a broader market caution, as the article notes that half of the existing analyst ratings on the stock are already equivalent to hold or sell. This suggests a growing consensus that the competitive landscape is intensifying, potentially eroding the market dominance and pricing power of Novo Nordisk's flagship products.

Key Decisions for Investors

• Investors should re-evaluate long positions in Novo Nordisk given the material price target cut and downgrade from a major firm, which validates growing concerns about competitive erosion.
• The heightened competitive risk from both Eli Lilly and compounding pharmacies suggests that the stock's previous growth premium may no longer be justified, warranting a cautious stance on new entries.
• Monitor market share data for Ozempic and Wegovy versus Eli Lilly's offerings, as this will be the key indicator validating or refuting UBS's bearish thesis.